In 2003 Prof. Dr. Andrea Pfeifer co-founded AC Immune where she holds since foundation the position of CEO. Prior to AC Immune she was head of Nestlé's Global Research in Lausanne, Switzerland and managed a a group of more than 600 people. While at Nestlé, she led the scientific development of the first Functional Food, LC1, and one of the first Cosmoceutical products in a joint venture with L’Oreal, Innéov Fermeté. She also co-founded the Nestlé Venture Capital Fund, a € 100Mio. Life Sciences corporate venture fund. She serves as chairwoman of the Biotechmedinvest AG Investment Fund, Basel and AB2Bio, Lausanne and is member of the Supervisory Board of Symrise AG, Holzminden. Prof. Pfeifer is a member of the the CEOi Initiative on Alzheimer’s Disease. She was recognized in 2009 as Technology Pioneer by the WEF and Swiss Entrepreneur of the Year by Ernst&Young. Additional recognitions include the BioAlps prize 2013, the election as one of the top 10 women in biotech from Fierce Biotech and one of the 300 most influential personalities in Switzerland. Prof. Pfeifer holds a PhD in Toxicology, Cancer Research from the University of Würzburg, Germany and continued with post-doctoral work in Molecular Carcinogenesis at the National Institutes of Health, Human Carcinogenesis Branch, in Bethesda, USA. She is a registered Toxicologist and Pharmacist, received her habilitation from the University of Lausanne, Switzerland and is an honorary professor at the Ecole Polytechnique Fédérale de Lausanne, Switzerland. She has published more than 200 papers and abstracts in leading scientific journals.

 Cancer Research